Researchers at Chi Mei Medical Center in Taiwan reported in Diabetology & Metabolic Syndrome on October 13, 2026 a records study in the TriNetX U.S. network that matched 176,981 women with overweight or obesity who started tirzepatide between 2022 and 2025 with the same number in lifestyle programs. Over up to two years, tirzepatide users had a lower rate of new endometrial cancer diagnoses (hazard ratio 0.717), a pattern seen across most subgroups. The authors said the observational, short-term findings do not establish that tirzepatide prevents the cancer.
A target trial emulation of more than 160,000 patients, published online June 7, 2026 in Annals of Oncology and presented at ASCO 2026, reported that adults with obesity but without diabetes who received GLP-1 receptor agonists had a 41% lower risk of obesity-associated cancers compared with non-users. Subgroup signals included a 68% reduction in men and a 58% reduction in endometrial cancer. Lead author Arthur Heng-Cheng Hsu (Houston Methodist Neal Cancer Center) and colleagues examined 13 obesity-associated cancers across the TriNetX nationwide database. The findings extend prior signals from the SELECT trial (cardiovascular benefit) and FLOW (kidney benefit) into oncology and add empirical weight behind the 21-expert global panel proposal for a 10-year prospective GLP-1 cancer-prevention trial first surfaced at ECO 2026 in Istanbul.